AstraZeneca (AZN) Price Target Raised to GBX 5,000 at Goldman Sachs Group
AstraZeneca (LON:AZN) had its price target boosted by Goldman Sachs Group from GBX 4,080 ($53.31) to GBX 5,000 ($65.33) in a research report sent to investors on Tuesday. They currently have a sell rating on the biopharmaceutical company’s stock.
AZN has been the topic of several other research reports. Barclays reissued an overweight rating on shares of AstraZeneca in a research report on Monday, January 21st. JPMorgan Chase & Co. reissued a buy rating on shares of AstraZeneca in a research report on Tuesday, January 22nd. Societe Generale boosted their target price on shares of AstraZeneca from GBX 8,400 ($109.76) to GBX 8,500 ($111.07) and gave the stock a buy rating in a research report on Wednesday, January 16th. Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a report on Monday, February 25th. Finally, Deutsche Bank reaffirmed a buy rating and issued a GBX 6,900 ($90.16) price objective on shares of AstraZeneca in a report on Monday, February 18th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company’s stock. AstraZeneca presently has a consensus rating of Buy and a consensus target price of GBX 6,282.20 ($82.09).
LON:AZN opened at GBX 6,312 ($82.48) on Tuesday. AstraZeneca has a twelve month low of GBX 4,260 ($55.66) and a twelve month high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: How Does the Quiet Period Work?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.